Shares rock­et up as Nabri­va Ther­a­peu­tics touts a PhI­II win for an­tibi­ot­ic

Two weeks af­ter its chief med­ical of­fi­cer re­signed, spark­ing jit­ters among the more hope­ful an­a­lysts fol­low­ing the com­pa­ny, Nabri­va Ther­a­peu­tics $NBRV an­nounced that its key Phase III study for the an­tibi­ot­ic lefa­mulin hit the pri­ma­ry end­point in prov­ing non-in­fe­ri­or to mox­i­floxacin for com­mu­ni­ty-ac­quired pneu­mo­nia.

The sched­uled de­par­ture of CMO El­yse Seltzer at the end of this month cre­at­ed some un­cer­tain­ty among the an­a­lysts like Leerink’s Paul Mat­teis, who had cred­it­ed Nabri­va — a No­var­tis spin­out helmed by Col­in Broom — with a 60% shot at suc­cess in this first-of-two Phase III stud­ies, dubbed LEAP I. Those fears proved un­found­ed, which ig­nit­ed a big ral­ly for its shares. Nabri­va’s stock soared 100% in pre-mar­ket trad­ing to­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER